BiotechTube
Home/Pipeline/Beta-lactam API Portfolio

Beta-lactam API Portfolio

Bacterial Infections

CommercialMarketed

Key Facts

Indication
Bacterial Infections
Phase
Commercial
Status
Marketed
Company
Nectar Lifesciences

About Nectar Lifesciences

Nectar Lifesciences operates a dual-strategy business model, combining a legacy, low-margin API manufacturing operation with a high-growth, direct-to-patient clinical services segment. Founded in 1995, the company has achieved significant scale with a $1.81B valuation, driven by its vertically integrated manufacturing capabilities and regulatory approvals from the US FDA and UK MHRA. Its strategic pivot into the US allergy care market represents a bold move to capture higher margins and recurring revenue from a large, underserved patient population, though it creates a unique and complex corporate profile.

View full company profile

Therapeutic Areas

Anti-infectivesAllergy & ImmunologyCardiologyGastroenterologyPain Management

Other Bacterial Infections Drugs

DrugCompanyPhase
Azithromycin Preparationscspc-pharmaceuticalCommercial
Penem Preparationscspc-pharmaceuticalCommercial
Various Penicillin/Cephalosporin Productscspc-pharmaceuticalCommercial
Nemonoxacin Malate CapsulesZhejiang MedicineCommercial
Generic Portfolio Expansion - Anti-infectivesAlkaloid AD SkopjeRegulatory Submission
Clindamycin Phosphate InjectionViwitCommercial
Levofloxacin Hydrochloride InjectionViwitCommercial
Meropenem-VaborbactamSciClone PharmaceuticalsCommercial (in China)
Vibativ® (telavancin)Cleo Life SciencesApproved
Penicillin V APIBiotikaCommercial
Sterile Injectable Antibiotics PortfolioSteripharmaApproved
Oral AntibioticDawah PharmaceuticalsANDA Filed/Pre-approval